SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein

Kuo,Shou-Jen; Lin,Hui-Yi; Chien,Su-Yu; Chen,Dar-Ren

doi:10.3892/or.2013.2470

SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein

Authors:
- Shou-Jen Kuo
- Hui-Yi Lin
- Su-Yu Chien
- Dar-Ren Chen
View Affiliations

Affiliations: Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 50006, Taiwan, R.O.C., Department of Pharmacology, School of Pharmacology, China Medical University, Taichung 40402, Taiwan, R.O.C., Department of Pharmacology, Changhua Christian Hospital, Changhua 50006, Taiwan, R.O.C.
Published online on: May 15, 2013 https://doi.org/10.3892/or.2013.2470
Pages: 125-130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Silent mating-type information regulation 2 homologue 1 (SIRT1), a member of the class III histone deacetylase (HDAC) family, is the mammalian ortholog of yeast Sir2. It has been reported to play a key role in a variety of physiological processes such as genomic stability, metabolism, neurogenesis and cell survival. The deacetylase function of SIRT1 has been suggested to play a role in prolonging the life of mammals. However, the suggested functions of SIRT1 as a potential tumor promoter have been challenged by observations of their respective downregulation and upregulation in various types of cancer. Breast cancer patients were included in the present study between 2007 and 2008. Their tumor tissues and paired normal breast tissues were collected and used for evaluation of the expression levels of SIRT1 and Ki67. The effects of SIRT1 on human breast cancer cell lines were also investigated. Immunohistochemistry showed that there is a high correlation between SIRT1 and Ki67 expression. Following treatment with sirtinol (inhibitor of SIRT1), the expression of the pro-survival protein Bcl-2 was markedly decreased in both MCF-7 and MDA-MB-231 cell lines, particularly in MDA-MB-231. Results of the present study revealed that inhibition of SIRT1 activity may be a promising chemotherapeutic strategy against breast cancer.

View Figures

View References

1	Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004. View Article : Google Scholar : PubMed/NCBI
2	Michan S and Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
3	Vaziri H, Dessain SK, Ng Eaton E, et al: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
4	Dai JM, Wang ZY, Sun DC, Lin RX and Wang SQ: SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol. 210:161–166. 2007. View Article : Google Scholar : PubMed/NCBI
5	Wong S and Weber JD: Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J. 407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
6	Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
7	Jung-Hynes B and Ahmad N: Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle. 8:1478–1483. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kuzmichev A, Margueron R, Vaquero A, et al: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA. 102:1859–1864. 2005. View Article : Google Scholar
9	Zhang Y, Zhang M, Dong H, et al: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 28:445–460. 2009. View Article : Google Scholar : PubMed/NCBI
10	Stünkel W, Peh BK, Tan YC, et al: Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2:1360–1368. 2007.
11	Kabra N, Li Z, Chen L, et al: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem. 284:18210–18217. 2009. View Article : Google Scholar : PubMed/NCBI
12	Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
13	Jang KY, Hwang SH, Kwon KS, et al: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 32:1523–1531. 2008. View Article : Google Scholar : PubMed/NCBI
14	Bradbury CA, Khanim FL, Hayden R, et al: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar
15	Yuan Z, Zhang X, Sengupta N, Lane WS and Seto E: SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell. 27:149–162. 2007. View Article : Google Scholar : PubMed/NCBI
16	Chu F, Chou PM, Zheng X, Mirkin BL and Rebbaa A: Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 65:10183–10187. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cheng HL, Mostoslavsky R, Saito S, et al: Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA. 100:10794–10799. 2003. View Article : Google Scholar : PubMed/NCBI
18	Matsushita N, Takami Y, Kimura M, et al: Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells. 10:321–332. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kojima K, Ohhashi R, Fujita Y, et al: A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun. 373:423–428. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yuan J, Minter-Dykhouse K and Lou Z: A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol. 185:203–211. 2009. View Article : Google Scholar : PubMed/NCBI
21	Firestein R, Blander G, Michan S, et al: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 3:e20202008. View Article : Google Scholar : PubMed/NCBI
22	Chua KF, Mostoslavsky R, Lombard DB, et al: Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab. 2:67–76. 2005. View Article : Google Scholar : PubMed/NCBI
23	Wang RH, Sengupta K, Li C, et al: Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 14:312–323. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lim CS: SIRT1: tumor promoter or tumor suppressor? Med Hypotheses. 67:341–344. 2006. View Article : Google Scholar : PubMed/NCBI
25	Li K and Luo J: The role of SIRT1 in tumorigenesis. N Am J Med Sci. 4:104–106. 2011. View Article : Google Scholar
26	Tavassoli FA and Devilee P; World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press; Lyon: 2003
27	Sung JY, Kim R, Kim JE and Lee J: Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci. 101:1738–1744. 2010. View Article : Google Scholar : PubMed/NCBI
28	Heltweg B, Gatbonton T, Schuler AD, et al: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66:4368–4377. 2006. View Article : Google Scholar
29	Ota H, Tokunaga E, Chang K, et al: Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 25:176–185. 2006.PubMed/NCBI
30	Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65:10457–10463. 2005. View Article : Google Scholar : PubMed/NCBI
31	Reed JC: Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 111:3322–3330. 2008. View Article : Google Scholar : PubMed/NCBI
32	Hockenbery DM: Targeting mitochondria for cancer therapy. Environ Mol Mutagen. 51:476–489. 2010. View Article : Google Scholar : PubMed/NCBI
33	Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC and Fornace AJ Jr: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60:6101–6110. 2000.PubMed/NCBI
34	Zhang M, Guo R, Zhai Y and Yang D: LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members. Cancer Lett. 195:201–210. 2003. View Article : Google Scholar
35	Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI